Abstract

The role of the hepatitis B virus (HBV) mutant G145R, with a single change in amino acid 145 of the surface protein, as a minor population remains unknown in mother-to-child transmission. The minor strain as well as the major strain of the G145R mutant were evaluated in three cohorts using a locked nucleic acid probe-based real-time PCR. The breakthrough cohort consisted of children who were born to HBV carrier mothers and became HBV carriers despite immnoprophylaxis (n = 25). The control cohort consisted of HBV carriers who had no history of receiving the hepatitis B vaccine, hepatitis B immunoglobulin or antiviral treatment (n = 126). The pregnant cohort comprised pregnant women with chronic HBV infection (n = 31). In the breakthrough cohort, 6 showed positive PCR results (major, 2; minor, 4). In the control cohort, 13 showed positive PCR results (major, 0; minor, 13). HBeAg-positive patients were prone to have the G145R mutant as a minor population. Deep sequencing was performed in a total of 32 children (PCR positive, n = 13; negative, n = 19). In the breakthrough cohort, the frequency of the G145R mutant ranged from 0.54% to 6.58%. In the control cohort, the frequency of the G145R mutant ranged from 0.42% to 4.1%. Of the 31 pregnant women, 4 showed positive PCR results (major, n = 0; minor, n = 4). All of the pregnant women were positive for HBeAg and showed a high viral load. Three babies born to 3 pregnant women with the G145R mutant were evaluated. After the completion of immunoprophylaxis, 2 infants became negative for HBsAg. The remaining infant became negative for HBsAg after the first dose of HB vaccine. G145R was detected in one-fourth of the children with immunoprophylaxis failure. However, the pre-existence of the G145R mutant as a minor population in pregnant women does not always cause breakthrough infection in infants.

Highlights

  • The hepatitis B (HB) vaccine, which prevents the transmission of hepatitis B virus (HBV), was introduced into routine immunization programs in 183 countries by 2013 [1], HBV infection remains a major global health problem

  • A prospective study was conducted to clarify whether immunoprophylaxis failure could occur in infants who were born to HBV carrier mothers with the G145R mutant existing as a minor population

  • The other was the breakthrough cohort comprising patients born to HBV carrier mothers who had breakthrough infection despite immunoprophylaxis with a series of 3 doses of HB vaccine plus hepatitis B immunoglobulin (HBIG)

Read more

Summary

Introduction

The hepatitis B (HB) vaccine, which prevents the transmission of hepatitis B virus (HBV), was introduced into routine immunization programs in 183 countries by 2013 [1], HBV infection remains a major global health problem. In intermediate-income and high-income countries, a series of 3 doses of HB vaccine plus hepatitis B immunoglobulin (HBIG) combined with a universal maternal screening program are administered to newborn babies born to HBV carrier mothers. In addition to a maternal high viral load, vaccine escape mutants (VEMs) can play a crucial role in immunoprophylaxis failure in MTCT [13,14,15,16,17]. The G145R mutant as a minor strain as well as a major strain was detected in chronically infected children with HBV due to breakthrough infection using LNA-based probe real-time PCR. A prospective study was conducted to clarify whether immunoprophylaxis failure could occur in infants who were born to HBV carrier mothers with the G145R mutant existing as a minor population

Methods
Results
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call